Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lowered its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 330,300 shares of the company's stock after selling 82,100 shares during the quarter. Prudential Financial Inc. owned approximately 0.60% of Voyager Therapeutics worth $1,873,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Picton Mahoney Asset Management lifted its position in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after acquiring an additional 2,444 shares in the last quarter. Intech Investment Management LLC acquired a new position in Voyager Therapeutics in the 3rd quarter valued at about $74,000. Virtu Financial LLC purchased a new position in Voyager Therapeutics in the 4th quarter valued at about $100,000. SG Americas Securities LLC lifted its holdings in Voyager Therapeutics by 86.7% in the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company's stock valued at $131,000 after purchasing an additional 10,704 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $216,000. Hedge funds and other institutional investors own 48.03% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. StockNews.com downgraded Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the stock an "overweight" rating in a report on Wednesday, March 12th. Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $13.97.

Voyager Therapeutics Trading Up 9.1 %

Shares of Voyager Therapeutics stock traded up $0.26 during trading hours on Wednesday, reaching $3.11. The stock had a trading volume of 706,718 shares, compared to its average volume of 462,863. Voyager Therapeutics, Inc. has a 1 year low of $2.76 and a 1 year high of $9.55. The firm has a 50 day simple moving average of $4.04 and a two-hundred day simple moving average of $5.43. The firm has a market capitalization of $171.69 million, a price-to-earnings ratio of 4.38 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the company earned $1.25 EPS. Sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 15,163 shares of company stock worth $59,158. Corporate insiders own 4.53% of the company's stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.